William T Hu

20230003744, Jan 5, 2023

Jun 16, 2022

17/842433

- New Brunswick NJ, US
- Atlanta GA, US
William T. Hu - New Brunswick NJ, US

G01N 33/68

Embodiments of the disclosure are directed to biomarkers, or a panel of biomarkers, that determine progression of Alzheimer's disease, and methods of use thereof.

20190062265, Feb 28, 2019

Aug 25, 2017

15/686500

- North Brunswick NJ, US
William S. Hu - Princeton NJ, US

C07C 227/40
C07C 227/42

There is disclosed a process for the purification of long chain amino acids by recrystallization in an aqueous solution of organic carboxylic acid in the absence or presence of solvent, comprising: (1) dissolving a long chain amino acid in an aqueous solution of organic carboxylic acid by heating; (2) cooling the solution of step (1) to crystallize the long chain amino acid; and (3) recovering the long chain amino acid of step (2) by means of solid-liquid separation.

20190062266, Feb 28, 2019

Dec 14, 2017

15/842251

- North Brunswick NJ, US
William S. Hu - Princeton NJ, US

C07C 227/42

There is disclosed a process for the purification of long chain amino acids by recrystallization in an aqueous solution of organic carboxylic acid in the absence or presence of solvent, comprising: (1) dissolving a long chain amino acid in an aqueous solution of organic carboxylic acid by heating; (2) cooling the solution of step (1) to crystallize the long chain amino acid; and (3) recovering the long chain amino acid of step (2) by means of solid-liquid separation.

20160146837, May 26, 2016

Sep 5, 2013

14/417672

- Atlanta GA, US
William T. Hu - Atlanta GA, US

Emory University - Atlanta GA

G01N 33/68

This disclosure relates to diagnostic testing for subjects with or at risk of dementia and methods related thereto. In certain embodiments, the disclosure relates to methods of diagnosing a frontotemporal lobar degeneration subtype comprising measuring total Tau and Tau phosphorylated at threonine 181 in a sample from a subject, calculating a ratio of Tau phosphorylated at threonine 181 to total Tau, and making a diagnosis of the subtype based on said ratios. Typically, the sample is of cerebrospinal fluid and the frontotemporal lobar degeneration subtypes are selected from frontotemporal lobar degeneration with immunoreactive lesions to Tau and frontotemporal lobar degeneration with immunoreactive lesions to TAR DNA binding protein of 43 kD.

20140228240, Aug 14, 2014

Feb 14, 2014

14/180844

- Atlanta GA, US
William Hu - Atlanta GA, US

Emory University - Atlanta GA

G01N 33/543

506 9, 506 39

This disclosure is in the area of medical diagnostics that provides a method to assist in diagnosis and monitoring the progression of Alzheimer's disease and mild cognitive impairment (MCI).